Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

Kedudukan dalam Saham #3263
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Harga Saham
$118.50
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.39B
Perubahan (1 hari)
0.01%
Perubahan (1 tahun)
133.68%
Negara
US
Perdagangan Haemonetics Corporation (HAE)

Kategori

Healthcare
Pendapatan untuk Haemonetics Corporation (HAE)
Pendapatan pada Jun 2026 TTM: $130.44M
Menurut laporan kewangan terkini Haemonetics Corporation, pendapatan semasa syarikat ialah $130.44M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $151.87M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $141.40M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Haemonetics Corporation dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $130.44M -38.49%
2025 $212.07M 39.64%
2024 $151.87M 7.40%
2023 $141.40M 122.23%
2022 $63.63M -12.73%
2021 $72.91M -16.34%
2020 $87.15M 18.36%
2019 $73.63M 23.48%
2018 $59.63M -317.03%
2017 $-27.48M -48.56%
2016 $-53.42M -271.40%
2015 $31.17M -14.38%
2014 $36.40M -27.05%
2013 $49.90M -44.25%
2012 $89.50M -18.70%
2011 $110.08M 35.45%
2010 $81.27M -4.39%
2009 $85.00M 9.96%
2008 $77.30M 6.87%
2007 $72.34M -32.32%
2006 $106.88M 78.61%
2005 $59.84M 30.62%
2004 $45.81M 18.66%
2003 $38.61M 0.26%
2002 $38.51M 122.24%
2001 $17.33M -36.59%
2000 $27.33M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$7.51B 5,658.42%
US
$5.56B 4,164.96%
IE
$5.15B 3,846.79%
US
$3.86B 2,860.10%
US
- -
DE